Community Acquired Pneumonia (CAP) has a high mortality rate. A new study evaluates the use of hydrocortisone for severe CAP in the ICU setting. Join host, Geoff Wall, as he evaluates if the evidence stacks up.

The GameChanger
The use of steroids to treat severe pneumonia has waxed and waned for many years with insufficient evidence. A recent study found steroids improved a number of outcomes, including mortality.

Show Segments
00:00 - Introductions
01:19 - Past Studies on CAP Treatment
03:32 - The CAPE Code Study
17:05 - The GameChanger: The Study Findings
24:31 - Connecting to Practice: Study Limitations
26:01 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Hydrocortisone in Severe Community-Acquired Pneumonia

Redeem your CPE here
CPE (Pharmacist)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Pharmacists: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the past history of major mortality studies for CAP pharmacotherapy
2. Discuss the CAPE Code study and its possible implications in the ICU

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-147-H01-P
Initial release date: 04/24/2023
Expiration date: 04/24/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram